Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Etoposide phosphate (BMY40481) is the phosphate salt of Etoposide (known as VP-16 and VP-16213), which is a chemotherapeutic drug used for the treatments of various cancers and is a semisynthetic derivative of podophyllotoxin which inhibits DNA synthesis via topoisomerase II inhibitory activity. Etoposide is extracted from the mandrake root Podophyllum peltatum. It possesses potent antineoplastic properties, and binds to and inhibits topoisomerase II. Etoposide works by ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
ln Vitro |
Etoposide phosphate is the solubility of etoposide and could be its prodrug; etoposide is identified by the presence of a phosphate group at the 4' position of its E ring [1]. The inhibitory effects of etoposide phosphate (0-1) on HCT116 FBXW+/+, FBXW-/-, and p53-/- are dose-dependent and have IC50 values of 0.945 μM, 0.375 µM, and 1.437 µM[2]. 6 hours) postpones the recovery of p53 in cells lacking FBXW7. Moreover, in FBXW7-/-cells, FBXW7 expression vanished [2].
|
---|---|
ln Vivo |
In female CD-1 mice, a single dosage of mortgage phosphate (IV; 50, 100, or 150 mg/kg) results in gradual analgesic rescue, righting crises, torsional limb splay, and paralysis.
|
Cell Assay |
Cell viability test[2]
Cell Types: FBXW+/+, FBXW-/- and p53-/- Cell Tested Concentrations: 0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibition of HCT116 FBXW+/+, FBXW-/- and p53-/- cell growth in concentrated form. Western Blot Analysis[2] Cell Types: HCT116 FBXW7+/+ or FBXW7-/- Cell Tested Concentrations: 25 μM Incubation Duration: 6 hrs (hours) Experimental Results: It shows that the recovery of p53 levels after DNA damage is mediated by FBXW7. |
Animal Protocol |
Animal/Disease Models: Female CD-1 mice[3]
Doses: 50, 100 or 150 mg/kg Route of Administration: intravenous (iv) (iv)injection; clinical symptoms[3]. Single dose Experimental Results: Under light microscopy (LM), degeneration of dorsal root ganglion cells in peripheral nerves, dorsal roots and dorsal cord of the spinal cord and axonal degeneration of their distal and proximal processes were observed at all doses. |
References |
[1]. Witterland AH, et al. Etoposide phosphate, the water soluble prodrug of etoposide. Pharm World Sci. 1996 Oct;18(5):163-70.
[2]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4. [3]. Bregman CL, et al. Etoposide- and BMY-40481-induced sensory neuropathy in mice.Toxicol Pathol. 1994 Sep-Oct;22(5):528-35. [4]. SUMMARY OF PRODUCT CHARACTERISTICS |
Molecular Formula |
C29H33O16P
|
---|---|
Molecular Weight |
668.53652
|
CAS # |
117091-64-2
|
SMILES |
C[C@@H]1OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O[C@@H]3C4=CC5=C(C=C4[C@@H](C6=CC(=C(C(=C6)OC)OP(=O)(O)O)OC)[C@@H]7[C@@H]3COC7=O)OCO5)O)O)O1
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4958 mL | 7.4790 mL | 14.9580 mL | |
5 mM | 0.2992 mL | 1.4958 mL | 2.9916 mL | |
10 mM | 0.1496 mL | 0.7479 mL | 1.4958 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.